

Immunization of Recombinant Membrane Protein in *Theileria sergenti*

Jin-ho Park, Seung-ok Lee, Joon-seok Chae^{*}, Oh-deog Kwon and Joo-mook Lee¹
College of Veterinary Medicine, Chonbuk National University, Chonju 561-756, Korea
^{*}School of Veterinary Medicine, UC Davis, USA

Theileria sergenti 재조합 항원단백질의 면역원성

박진호 · 이승옥 · 채준석* · 권오덕 · 이주목¹
전북대학교 수의과대학, *UC Davis 수의과대학

요 약 : Theileriosis에 대한 효율적인 예방대책을 마련하기 위한 일환으로 발현된 *T. sergenti* 재조합 항원단백질의 면역원성을 조사하였다. 먼저, *E. coli* 단백질 발현 vector인 pQE 32 plasmid vector를 이용하여 발현된 *T. sergenti*의 재조합 막표면단백질(KTs-MP)을 4개월령의 유우 송아지에 접종하였다. 그리고 접종된 송아지의 혈액변화상과 *T. sergenti*에 대한 항체가의 변화상을 분석한 결과, 재조합단백질의 접종에 의하여 항체가가 상승되는 것을 알 수 있었다. 그러나 재조합단백질의 접종만으로는 *T. sergenti*의 감염을 완전하게 예방하지는 못하였다.

Key words : *Theileria sergenti*, Recombinant protein, ELISA

Introduction

Theileriosis, caused by *Theileria sergenti* infection, divided into a peracute, acute, subacute, mild or chronic forms¹⁸. A common and major clinical sign with all forms of bovine theileriosis is anemia, and last for 4~20 days¹⁸. For example, depression, hyperthermia, retarded growth, reduced milk production are due to a severe anemia. Also, theileriosis brought great economic loss in cattle of Korea²⁰.

Many studies indicate that anemia is introduced by the effects of opsonin with auto-immune responses against infected erythrocytes. Asaoka *et al.*¹ reported that macrophage are significantly activated within one month after inoculation, and these phenomenon appeared earlier than parasitaemia or the peak of antibody titer against *T. sergenti*^{4,16}. Hagiwara *et al.* reported that a significant hemolytic activity is observ-

ed in the infected blood when parasitemia is in high phase^{5,17}. But, the process of anemia is not clearly established yet.

Because of low mortality of mild or chronic theileriosis, many of veterinarian and farmer frequently ignore the significance of the consumptive disease. The individual treatment against theileriosis is require expensive veterinary and other charge, so the prevention or group management should be established for the control of theileriosis.

Research on the control of parasitic diseases through vaccination has been recently stimulated by the advance in immunology and biotechnology. In a general immunological aspect, the best way to prevent disease is immunization with a safe and effective vaccines. Hooshmand⁸ reported that the hemoparasitic infection could be controlled by vaccination as in virus or bacteria infection. Also, several forms of live or killed vaccines were used to prevent theileriosis. But these vaccines were not effective to use in practice⁸. In this study, we evaluate the immunization effects of the purified recombinant *T. sergenti* membrane protein (KTs-MP) *in vivo*.

이 논문은 1999년도 전북대학교 생체안전성연구소 학술연구비의 일부 지원으로 이루어 졌음(CNU-BSRI, No. 99-10).

¹Corresponding author.




Fig 1. Levels of anti-*T. sergenti* antibody response after injection of recombinant KT_s-MP protein.

Materials and Methods

Experimental Animal

The immunogenicity test were performed to evaluate the effect of recombinant KT_s-MP *in vivo*. Four months of Holstein calves were used in this study. Among the healthy fifteen calves, ten were chosen as a experimental (injected) group, and five as a control (not-injected) group.

Immunization

The purified recombinant KT_s-MP were adjusted to 0.5 mg/ml according to the standard procedure¹⁰ and injected into the experimental animals to evaluate the effects of recombinant protein immunization *in vivo*. Booster immunization was performed twice at successive 3 weeks interval following the initial injection. The experimental animals were immunized with 2 mg of recombinant KT_s-MP protein in a total volume of 4 ml.

Parameter of Evaluation

Prior to the immunization, all of the calves were checked with hematological values and antibody titer against *T. sergenti*.

Hematological Examination

The whole blood and serum were collected from experimental and control calves. Erythrocyte count (RBC) and hemoglobin concentration (Hb) were checked by automatic blood analyzer (MINOS-VET, Japan), and Hematocrit (PCV) were measured by

microhematocrit method. Hematograms of experimental group were compared with those of control group on the same times.

ELISA

The level of KT_s-MP specific antibody in calf's sera were measured by ELISA¹³. For ELISA, each wells of the microtiter plate were coated with 0.5 µg of isolated *T. sergenti* protein in 50 µl of coating buffer, washed three times with PBS/0.05% Tween-20 and 200 µl of blocked with blocking solution. Calves' sera serially diluted in PBS was added into well and anti-bovine IgG conjugated with AP was added onto each well. Absorbance was measured at 405 nm by using ELISA reader (Spectra Count, Packard instrument Co., USA). The antibody level of experimental group against *T. sergenti* was compared to control group on the same times.

Results

Hematological Values

Prior to the immunization, the mean values of PCV (%), Hb (g/dl) and RBC ($\times 10^6/\mu\text{l}$) were 30.2, 10.6 and 5.5 in the experimental group, respectively. The same items were 33.2, 11.3 and 7.5 in the control group, respectively. These data showed the mean values of

Table 1. Hematological Values of Experimental (Injected with Recombinant KT_s-MP) and Control Calves

	Experimental group (n=10)	Control group (n=5)
0 weeks		
PCV(%)	30.2	33.2
Hb(g/dl)	10.6	11.3
RBC($\times 10^6/\mu\text{l}$)	5.5	7.5
3 weeks		
PCV(%)	28.1 (-7%)	29.8 (-11%)
Hb(g/dl)	8.7 (-18%)	9.2 (-18%)
RBC($\times 10^6/\mu\text{l}$)	5.4 (-3%)	6.2 (-17%)
6 weeks		
PCV(%)	24.3 (-20%)	22.6 (-32%)
Hb(g/dl)	7.9 (-25%)	7.2 (-36%)
RBC($\times 10^6/\mu\text{l}$)	4.4 (-21%)	4.3 (-43%)
9 weeks		
PCV(%)	25.6 (-15%)	25.2 (-24%)
Hb(g/dl)	9.5 (-10%)	9.5 (-16%)
RBC($\times 10^6/\mu\text{l}$)	6.3 (+11%)	5.5 (-27%)

(); Decreased percentage compare with the preinjected data

PCV, Hb and RBC in control group were higher than experimental group

But six weeks later, the mean values of PCV, Hb and RBC in experimental group were higher than control group (Table 1). The mean values of PCV (%), Hb (g/dl), and RBC ($\times 10^6/\mu\text{l}$) were 24.3, 7.9 and 4.4 in the experimental group, respectively. The same items were 22.6, 7.2 and 4.3 in the control group, respectively.

Antibody Titer Against *T. sergenti*

The level of antibody titer was significantly increased by 6 weeks after inoculation in experimental group whereas the control group showed no significant change by 6 week (Fig 1).

Discussion

Theileriosis is a protozoan disease that causing anemia, hyperthermia, reduced milk production, and severe economic loss of cattle industry in Korea¹⁹. If the cattle which previously infected with *T. sergenti* are exposed to strong stress or infected with other disease, they become severe anemia, icterus and pyrexia or death²¹. In the view of diagnosis, the diagnostic method progressed from the microscope examination to the molecular biological methods for the rapid and sensitive diagnosis. In molecular biological diagnostic methods, Southern hybridization using DNA probe, PCR amplification on the base sequenced target gene, phylogenetic assay using 18s rRNA, Western blotting proved antigenic protein were continually developed^{3,9,11}.

The several effective prevention methods against theileriosis were reported. Hooshmand *et al.* reported that vaccination by tissue culture was effective for prevention of theileriosis^{2,8}. However, owing to the difficulty of culture of *Theileria* spp., tissue culture vaccines are thought to be not feasible yet.

Most of the reports described about the effects of vaccination with recombinant protein to control the diseases including babesiosis and theileriosis^{7,12,14}. Hines *et al.*⁶ reported that vaccination with recombinant protein can produced high-antibody titer but does not reflect *in vivo* protective immunity to babe-

siosis. In this experiment, calves immunized with recombinant KTS-MP showed the increased antibody titer to *T. sergenti* compared with control calves. But immunization with recombinant protein could not perfectly prevent challenged with field *T. sergenti*.

Conclusions

The purified recombinant antigenic protein of *T. sergenti* was evaluated for its immunogenicity *in vivo*. Holstein calves were immunized with the purified KTs-MP by 3 weeks interval. Then, the hematological values and the antibody titer against *T. sergenti* were checked from 0 to 9 weeks at successive 3 week intervals. The antibody titer of calves immunized with recombinant KTs-MP were increased significantly. But, the immunization with recombinant protein didn't protected perfectly challenged with field *T. sergenti*.

Reference

1. Asaoka H, Onuma M, Kawamoto S, *et al.* Activation of bovine peripheral blood macrophages in *Theileria sergenti* infected calves. *Res Vet Sci* 1991; 50(1): 23-28.
2. Baek BK, Choi IH, Kim BS, *et al.* Immunogenicity and protective efficacy of solubilized merozoite enriched *Theileria sergenti* immunogens. I: Protection against homologous stabiliate challenge. *Kisaeng-chunghak Chapchi* 1992; 30(2): 133-140.
3. Chae JS, Lee JM, Kwon OD, *et al.* Rapid detection of *Theileria sergenti* by the polymerase chain reaction in Korean cattle. *Korean J Vet Res* 1996; 36(3): 195-207.
4. Diesing L, Ahmed JS, Schein E. Application of chemi- and bioluminescence in studies of immunological reactions against protozoa. *Vet Parasitol* 1986; 20(1-3): 229-235.
5. Hagiwara K, Tsuji M, Ishihara C, *et al.* Serum from *Theileria sergenti*-infected cattle accelerates the clearance of bovine erythrocytes in SCID mice. *Parasitol Res* 1995; 81(6): 470-474.
6. Hines SA, Palmer GH, Jasmer DP, *et al.* Immunization of cattle with recombinant *Babesia bovis* merozoite surface antigen-1. *Infect Immun* 1995; 63(1): 349-352.
7. Honda Y, Waithaka M, Taracha EL, *et al.* Delivery of the *Theileria parva* p67 antigen to cattle using recombinant vaccinia virus: IL-2 enhances protection. *Vaccine* 1998; 16(13): 1276-1282.

8. Hooshmand-Rad P. The use of tissue culture attenuated live vaccine for *Theileria hirci*. *Dev Biol Stand* 1985; 62: 119-127.
9. Kawazu S, Sugimoto C, Kamio T, *et al.* Analysis of the genes encoding immunodominant piroplasm surface proteins of *T. sergenti* and *T. buffeli* by nucleotide sequencing and polymerase chain reaction. *Mol Biochem Parasitol* 1992; 56(1): 169-175.
10. Lowry OH, Rosenbrough NJ, Farr AL, *et al.* Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193: 253-261.
11. Matsuba T, Kawakami Y, Iwai H, *et al.* Genomic analysis of *Theileria sergenti* stocks in Japan with DNA probes. *Vet Parasitol* 1992; 41(1-2): 35-43.
12. Musoke A, Morzaria S, Nkonge C, *et al.* A recombinant sporozoite surface antigen of *Theileria parva* induces protection in cattle. *Proc Natl Acad Sci USA* 1992; 89(2): 514-518.
13. Ohgitani T, Okabe T, Sasaki N. Antigenic properties of *Theileria sergenti* in ELISA serodiagnosis. *Nippon Juigaku Zasshi* 1987; 49(3): 531-534.
14. Onuma M, Kubota S, Kakuda T, *et al.* Control of *Theileria sergenti* infection by vaccination. *Trop Anim Health Prod* 1997; 29: 119-123.
15. Schein E. On the life cycle of *Theileria annulata* in the midgut and hemolymph of *Hyalomma anatolicum excavatum*. *Z Parasitenkd* 1975; 47(2): 165-167.
16. Shinkawa S, Onuma M, Matsuba T, *et al.* Opsonization of merozoites with sera from *Theileria sergenti*-infected calves. *Nippon Juigaku Zasshi* 1990; 52(6): 1289-1291.
17. Yagi Y, Furuuchi S, Takahashi H, *et al.* Abnormality of osmotic fragility and morphological disorder of bovine erythrocytes infected with *Theileria sergenti*. *Nippon Juigaku Zasshi* 1989; 51(2): 389-395.
18. 南哲郎. 牛: *Theileria* 病. 南哲郎, 脇永 徹 編著, 獣醫住血微生物病. 東京: 近代出版, 1986; 149-169.
19. 전영. 국내 소의 주혈원충과 그 혈액학치에 관한 조사 연구. *농시보고* 1971; 12: 81-85.
20. 한치우, 김삼기. 한우에 있어서 우의 파이로플라스마 원충의 분포조사 및 인공감염시험. *농시보고* 1965; 11: 59-70.
21. 한치우. 우리나라 축우의 소위 소형 *Piroplasma*병에 관한 연구 II. 소위 소형 *Piroplasma*를 매개하는 진드기에 관하여. *가축위생연구보고* 1971; 14: 97-107.